Literature DB >> 14673154

Mdm2 regulates p53 independently of p19(ARF) in homeostatic tissues.

Kathleen A O'Leary1, Susan M Mendrysa, Abram Vaccaro, Mary Ellen Perry.   

Abstract

Tumor suppressor proteins must be exquisitely regulated since they can induce cell death while preventing cancer. For example, the p19(ARF) tumor suppressor (p14(ARF) in humans) appears to stimulate the apoptotic function of the p53 tumor suppressor to prevent lymphomagenesis and carcinogenesis induced by oncogene overexpression. Here we present a genetic approach to defining the role of p19(ARF) in regulating the apoptotic function of p53 in highly proliferating, homeostatic tissues. In contrast to our expectation, p19(ARF) did not activate the apoptotic function of p53 in lymphocytes or epithelial cells. These results demonstrate that the mechanisms that control p53 function during homeostasis differ from those that are critical for tumor suppression. Moreover, the Mdm2/p53/p19(ARF) pathway appears to exist only under very restricted conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14673154      PMCID: PMC303350          DOI: 10.1128/MCB.24.1.186-191.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  21 in total

1.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

2.  Oligomerization of the human ARF tumor suppressor and its response to oxidative stress.

Authors:  Sergio Menéndez; Zeb Khan; David W Coomber; David P Lane; Maureen Higgins; Maria M Koufali; Sonia Lain
Journal:  J Biol Chem       Date:  2003-02-11       Impact factor: 5.157

3.  Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging.

Authors:  F Zindy; D E Quelle; M F Roussel; C J Sherr
Journal:  Oncogene       Date:  1997-07-10       Impact factor: 9.867

4.  Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.

Authors:  T Kamijo; F Zindy; M F Roussel; D E Quelle; J R Downing; R A Ashmun; G Grosveld; C J Sherr
Journal:  Cell       Date:  1997-11-28       Impact factor: 41.582

5.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.

Authors:  R Montes de Oca Luna; D S Wagner; G Lozano
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

6.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

7.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

8.  INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.

Authors:  Anette Weber; Ulf Bellmann; Friedrich Bootz; Christian Wittekind; Andrea Tannapfel
Journal:  Virchows Arch       Date:  2002-04-04       Impact factor: 4.064

9.  Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential.

Authors:  Y Barak; E Gottlieb; T Juven-Gershon; M Oren
Journal:  Genes Dev       Date:  1994-08-01       Impact factor: 11.361

10.  mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation.

Authors:  Susan M Mendrysa; Matthew K McElwee; Jennifer Michalowski; Kathleen A O'Leary; Karen M Young; Mary Ellen Perry
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

View more
  11 in total

1.  Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity.

Authors:  Hussein A Abbas; Daniela R Maccio; Suleyman Coskun; James G Jackson; Amy L Hazen; Tiffany M Sills; M James You; Karen K Hirschi; Guillermina Lozano
Journal:  Cell Stem Cell       Date:  2010-11-05       Impact factor: 24.633

2.  Distinct E2F-mediated transcriptional program regulates p14ARF gene expression.

Authors:  Hideyuki Komori; Mitsuru Enomoto; Masataka Nakamura; Ritsuko Iwanaga; Kiyoshi Ohtani
Journal:  EMBO J       Date:  2005-10-06       Impact factor: 11.598

Review 3.  The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.

Authors:  Christine M Eischen; Guillermina Lozano
Journal:  Hum Mutat       Date:  2014-03-06       Impact factor: 4.878

4.  Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.

Authors:  Chandrashekhar Korgaonkar; Jussara Hagen; Van Tompkins; April A Frazier; Chantal Allamargot; Frederick W Quelle; Dawn E Quelle
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

Review 5.  The Role of E3 Ligase Pirh2 in Disease.

Authors:  Alexandra Daks; Olga Fedorova; Sergey Parfenyev; Ivan Nevzorov; Oleg Shuvalov; Nickolai A Barlev
Journal:  Cells       Date:  2022-04-30       Impact factor: 7.666

6.  The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival.

Authors:  Y A Valentin-Vega; H Okano; G Lozano
Journal:  Cell Death Differ       Date:  2008-07-18       Impact factor: 15.828

7.  Decreased Mdm2 expression inhibits tumor development and extends survival independent of Arf and dependent on p53.

Authors:  Christine M Eischen; Kelli Boyd
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

8.  Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction.

Authors:  Peter M Fischer
Journal:  Int J Pept Res Ther       Date:  2006-03-15       Impact factor: 1.931

9.  p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.

Authors:  S B Vestey; C Sen; C J Calder; C M Perks; M Pignatelli; Z E Winters
Journal:  Breast Cancer Res       Date:  2004-07-29       Impact factor: 6.466

Review 10.  Targeting the p53-MDM2 interaction to treat cancer.

Authors:  C Klein; L T Vassilev
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.